ArticleScientific reports2017
Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications.Medical oncology (Northwood, London, England) · 2026Review
- PD-1H (VISTA) Expression in Cutaneous Squamous Cell Carcinoma Is Correlated with T-Cell Infiltration and Activation.The Journal of investigative dermatology · 2025Article
- Leveraging T cells for cancer immunotherapy.Immunity & inflammation · 2025Review
- A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy.Biomarker research · 2024Review
- VISTA-mediated immune evasion in cancer.Experimental & molecular medicine · 2024Review
- Altered characteristics of regulatory T cells in target tissues of Sjögren's syndrome in murine models.Molecular immunology · 2024Article
- Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.Frontiers in immunology · 2024Review
- Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection.Frontiers in immunology · 2023Review
- VISTA expression and patient selection for immune-based anticancer therapy.Frontiers in immunology · 2023Review
- Negative Immune Checkpoint Protein, VISTA, Regulates the CD4Frontiers in immunology · 2022Article
- The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.Scientific reports · 2021Article
- Exploring the VISTA of microglia: immune checkpoints in CNS inflammation.Journal of molecular medicine (Berlin, Germany) · 2020Review
- New emerging targets in cancer immunotherapy: the role of VISTA.ESMO open · 2020Review
- VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance.Science (New York, N.Y.) · 2020Article
- Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
- Regulatory T Cells Beyond Autoimmunity: From Pregnancy to Cancer and Cardiovascular Disease.Frontiers in immunology · 2020Review
- VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.Seminars in immunology · 2019Review
- CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β.PLoS biology · 2018Article
- VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.Cancer immunology, immunotherapy : CII · 2018Article
- VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.Arthritis research & therapy · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
Programmed death one homolog (PD-1H) is an immunoglobulin superfamily molecule and primarily acts as a coinhibitor in the initiation of T cell response to antigens. Here, we report that genetic ablation of PD-1H in mice blocks the differentiation of naive T cells to Foxp3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.